113 related articles for article (PubMed ID: 27267254)
21. Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study.
Chattopadhyay N; Riecke K; Ligges S; Zimmermann T; Halabi A; Schultze-Mosgau MH
Br J Clin Pharmacol; 2019 Sep; 85(9):2011-2021. PubMed ID: 31112623
[TBL] [Abstract][Full Text] [Related]
22. Effect of hepatic impairment on the pharmacokinetics of a single dose of cilostazol.
Bramer SL; Forbes WP
Clin Pharmacokinet; 1999; 37 Suppl 2():25-32. PubMed ID: 10702884
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function.
Lau AH; Gustavson LE; Sperelakis R; Lam NP; El-Shourbagy T; Qian JX; Layden T
Epilepsia; 1997 Apr; 38(4):445-51. PubMed ID: 9118850
[TBL] [Abstract][Full Text] [Related]
24. Physiologically-based pharmacokinetic model for alectinib, ruxolitinib, and panobinostat in the presence of cancer, renal impairment, and hepatic impairment.
Alsmadi MM; Al-Daoud NM; Jaradat MM; Alzughoul SB; Abu Kwiak AD; Abu Laila SS; Abu Shameh AJ; Alhazabreh MK; Jaber SA; Abu Kassab HT
Biopharm Drug Dispos; 2021 Jun; 42(6):263-284. PubMed ID: 33904202
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study.
Lasseter KC; Dilzer SC; Vargas R; Waldman S; Noveck RJ
Clin Pharmacokinet; 2004; 43(2):121-9. PubMed ID: 14748620
[TBL] [Abstract][Full Text] [Related]
26. An Open-Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics.
Li Y; Wang X; Liu L; Zhang C; Gomez D; Reyes J; Palmisano M; Zhou S
Clin Pharmacol Drug Dev; 2019 Apr; 8(3):346-354. PubMed ID: 29746728
[TBL] [Abstract][Full Text] [Related]
27. The pH-altering agent omeprazole affects rate but not the extent of ibrutinib exposure.
de Jong J; Haddish-Berhane N; Hellemans P; Jiao J; Sukbuntherng J; Ouellet D
Cancer Chemother Pharmacol; 2018 Aug; 82(2):299-308. PubMed ID: 29882017
[TBL] [Abstract][Full Text] [Related]
28. Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment.
Grasela DM; Christofalo B; Kollia GD; Duncan G; Noveck R; Manning JA; LaCreta FP
Pharmacotherapy; 2000 Jun; 20(6 Pt 2):87S-94S. PubMed ID: 10850525
[TBL] [Abstract][Full Text] [Related]
29. Effect of hepatic or renal impairment on eltrombopag pharmacokinetics.
Bauman JW; Vincent CT; Peng B; Wire MB; Williams DD; Park JW
J Clin Pharmacol; 2011 May; 51(5):739-50. PubMed ID: 20663991
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment.
Marzin K; Kretschmar G; Luedtke D; Kraemer S; Kuelzer R; Schlenker-Herceg R; Schmid U; Schnell D; Dallinger C
J Clin Pharmacol; 2018 Mar; 58(3):357-363. PubMed ID: 29106740
[TBL] [Abstract][Full Text] [Related]
31. Ibrutinib brain distribution: a preclinical study.
Goldwirt L; Beccaria K; Ple A; Sauvageon H; Mourah S
Cancer Chemother Pharmacol; 2018 Apr; 81(4):783-789. PubMed ID: 29476222
[TBL] [Abstract][Full Text] [Related]
32. Brigatinib pharmacokinetics in patients with chronic hepatic impairment.
Hanley MJ; Kerstein D; Tugnait M; Narasimhan N; Marbury TC; Venkatakrishnan K; Gupta N
Invest New Drugs; 2023 Jun; 41(3):402-410. PubMed ID: 37052729
[TBL] [Abstract][Full Text] [Related]
33. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
[TBL] [Abstract][Full Text] [Related]
34. Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment.
Frost CE; Ly V; Garonzik SM
Drugs R D; 2021 Dec; 21(4):375-384. PubMed ID: 34363188
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.
Gupta N; Hanley MJ; Venkatakrishnan K; Perez R; Norris RE; Nemunaitis J; Yang H; Qian MG; Falchook G; Labotka R; Fu S
Br J Clin Pharmacol; 2016 Sep; 82(3):728-38. PubMed ID: 27121262
[TBL] [Abstract][Full Text] [Related]
36. The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib.
Srinivas N; Barbour AM; Epstein N; Zhou G; Petusky S; Xun Z; Yuska B; Marbury T; Chen X; Yeleswaram S; Punwani N
J Clin Pharmacol; 2020 Aug; 60(8):1022-1029. PubMed ID: 32149388
[TBL] [Abstract][Full Text] [Related]
37. Open-label study of the safety and pharmacokinetics of solifenacin in subjects with hepatic impairment.
Kuipers M; Smulders R; Krauwinkel W; Hoon T
J Pharmacol Sci; 2006 Dec; 102(4):405-12. PubMed ID: 17170513
[TBL] [Abstract][Full Text] [Related]
38. Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study.
Peveling-Oberhag J; Zeuzem S; Yong WP; Kunz T; Paquet T; Bouillaud E; Urva S; Anak O; Sellami D; Kobalava Z
Clin Ther; 2013 Mar; 35(3):215-25. PubMed ID: 23453404
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment.
Xu Y; Izumi R; Nguyen H; Kwan A; Kuo H; Madere J; Slatter JG; Podoll T; Vishwanathan K; Marbury T; Smith W; Preston RA; Sharma S; Ware JA
J Clin Pharmacol; 2022 Jun; 62(6):812-822. PubMed ID: 34897701
[TBL] [Abstract][Full Text] [Related]
40. The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor.
Sarapa N; Britto MR; Mainka MB; Parivar K
Eur J Clin Pharmacol; 2005 Jun; 61(4):247-56. PubMed ID: 15887009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
